Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety
of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment
elevation myocardial infarction (STEMI) patients following percutaneous coronary intervention
(PCI) using point-of-care genetic testing for the CYP2C19*2, *17, and ABCB1 3435 C>T alleles.